Details of the Drug

General Information of Drug (ID: DMW8QNG)

Drug Name

Brolucizumab

Indication

Disease Entry	ICD 11	Status	REF
Wet age-related macular degeneration	9B78.3Z	Approved	[1]
Diabetic macular edema	9B71.02	Phase 3	[2]
------------------------------------------------------------------------------------

ATC Code

S01LA06: Brolucizumab

S01LA: Antineovascularisation agents

S01L: OCULAR VASCULAR DISORDER AGENTS

S01: OPHTHALMOLOGICALS

S: SENSORY ORGANS

Drug Type

Antibody

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 2480 mcgh/L [3]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 20.7 mcg/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 20.3 h [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 4.4 +/- 2.0 days [4]
Metabolism: The drug is metabolized via proteolysis to smaller peptides and amino acids [5]

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Vascular endothelial growth factor (VEGF)	TT9HKJA	VEGFA_HUMAN ; VEGFB_HUMAN ; VEGFC_HUMAN ; VEGFD_HUMAN	Inhibitor	[6]
Vascular endothelial growth factor A (VEGFA)	TTOHSBA	VEGFA_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Wet age-related macular degeneration

ICD Disease Classification

9B78.3Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Vascular endothelial growth factor A (VEGFA)	DTT	VEGFA	3.61E-01	0.15	0.47

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2	ClinicalTrials.gov (NCT04058067) To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema (KINGLET). U.S. National Institutes of Health.
3	Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration
4	FDA Approved Drug Products: BEOVU (brolucizumab) intravitreal injection
5	Li K, Xu Y: Citrate metabolism in blood transfusions and its relationship due to metabolic alkalosis and respiratory acidosis. Int J Clin Exp Med. 2015 Apr 15;8(4):6578-84. eCollection 2015.
6	Brolucizumab: First Approval. Drugs. 2019 Dec;79(18):1997-2000.